JANSSEN PHARMACEUTICALS, INC.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
 
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 43212
 
 
 
C07D HETEROCYCLIC COMPOUNDS 34128
 
 
 
C07K PEPTIDES 8128
 
 
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 3164
 
 
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 247
 
 
 
C07C ACYCLIC OR CARBOCYCLIC COMPOUNDS 2136
 
 
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 194
 
 
 
A23L FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT 163
 
 
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 198
 
 
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 1205

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2018/0021,360 Combination Therapy Regimen For Treatment Of Selected HCV GenotypesJul 21, 17Jan 25, 18[A61K]
2018/0021,361 COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTIONJul 21, 17Jan 25, 18[A61K]
2017/0319,572 COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTIONJul 25, 17Nov 09, 17[A61K]
2017/0152,253 Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCVFeb 10, 17Jun 01, 17[C07D, C07C]
2017/0087,174 COMBINATION THERAPY REGIMEN FOR TREATMENT OF HCVSep 29, 16Mar 30, 17[A61K]
2017/0051,069 ANTI-CD134 (OX40) ANTIBODIES AND USES THEREOFAug 25, 16Feb 23, 17[C07K]
2016/0251,345 Amorphous Salt of a Macrocyclic Inhibitor of HCVMar 08, 16Sep 01, 16[C07D]
2016/0206,645 COMBINATION THERAPIES FOR TREATMENT OF HCVJan 20, 16Jul 21, 16[A61K]

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9814699 Chemical compoundsFeb 10, 16Nov 14, 17[A61K, C07D]
9790281 Humanized anti-CD134 (OX40) antibodies and uses thereofMar 20, 14Oct 17, 17[A61K, C07K]
9737533 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disordersNov 19, 15Aug 22, 17[A61K, C07D]
9605082 Thrombin-binding antibody molecules and uses thereofJul 11, 16Mar 28, 17[A61K, C07K]
9586893 Processes and intermediates for preparing a macrocyclic protease inhibitor of HCVMar 16, 11Mar 07, 17[C07D, C07C]
9518128 Thrombin-binding antibody moleculesJun 19, 14Dec 13, 16[A61K, C07K]
9518129 Thrombin-binding antibody molecules and uses thereofDec 14, 12Dec 13, 16[A61K, C07K]
9475880 Anti-CD134 (OX40) antibodies and uses thereofSep 13, 12Oct 25, 16[G01N, C07K]
9328108 Process for preparing an intermediate of the macrocyclic protease inhibitor TMC 435Feb 09, 15May 03, 16[C07D]
9321758 Amorphous salt of a macrocyclic inhibitor of HCVFeb 26, 10Apr 26, 16[A61K, C07D]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2015/0209,366 COMBINATION OF A MACROCYCLIC PROTEASE INHIBITOR OF HCV, A NON-NUCLEOSIDE HCV INHIBITOR AND RITONAVIRAbandonedAug 30, 13Jul 30, 15[A61K]
8796311 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivativesWithdrawnMar 07, 08Aug 05, 14[A61K, C07D]
2013/0230,459 RADIOLABELLED mGluR2 PET LIGANDSAbandonedNov 08, 11Sep 05, 13[A61K, C07D, G01N, C07B]
2013/0210,868 STABLE TOPICAL COMPOSITIONS FOR 1,2,4-THIADIAZOLE DERIVATIVESAbandonedMar 15, 13Aug 15, 13[A61K]
2013/0203,823 STABLE TOPICAL COMPOSITIONS FOR 1,2,4-THIADIAZOLE DERIVATIVESAbandonedMar 15, 13Aug 08, 13[A61K]
2013/0196,992 1',3'-DISUBSTITUTED-4-PHENY-3,4,5,6-TETRAHYDRO-2H,1'H-[1,4']BIPYRIDINYL-2'-ONESAbandonedMar 14, 13Aug 01, 13[A61K, C07D]
2013/0109,652 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORSAbandonedDec 20, 12May 02, 13[C07F, C07D]
2013/0028,865 Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a NucleosideAbandonedApr 13, 11Jan 31, 13[A61K, A61P]
2012/0201,770 TREATMENT OF SWEATINGAbandonedFeb 01, 12Aug 09, 12[A61K, A61Q]
2010/0273,838 STABLE TOPICAL COMPOSITIONS FOR 1,2,4-THIADIAZOLE DERIVATIVESAbandonedApr 23, 10Oct 28, 10[A61K, A61P]
2010/0063,092 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVESAbandonedMar 07, 08Mar 11, 10[A61K, C07D, A61P]
7449575 Substituted diamino-1,3,5-triazine derivativesExpiredAug 12, 05Nov 11, 08[C07D]
2004/0071,671 Cell therapy method for the treatment of tumorsAbandonedNov 07, 02Apr 15, 04[A61K]
2003/0125,326 Farnesyl protein transferase inhibitor combinationsAbandonedAug 28, 02Jul 03, 03[A61K]
2003/0060,480 Farnesyl protein transferase inhibitor combinations with vinca alkaloidsAbandonedAug 28, 02Mar 27, 03[A61K]
2003/0050,323 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivativesAbandonedAug 28, 02Mar 13, 03[A61K]
5807576 Rapidly dissolving tabletExpiredFeb 03, 94Sep 15, 98[A61K]
5776491 Rapidly dissolving dosage formExpiredJun 07, 95Jul 07, 98[A61K]
5635210 Method of making a rapidly dissolving tabletExpiredDec 08, 94Jun 03, 97[A61K]
5215756 Preparation of pharmaceutical and other matrix systems by solid-state dissolutionExpiredNov 06, 90Jun 01, 93[A61K]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.